You can buy or sell ORMP and other stocks, options, ETFs, and crypto commission-free!
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Read More The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 7
ORMP: Data from Phase 1 Trial of Oral GLP-1 in 2Q19…
By David Bautz, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Business Update Oramed Pharmaceuticals Inc. (ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0801, an oral insulin, that is currently being tested in both type 1 (T1D) and type 2 diabetics (T2D). The company is also developing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1). ORMD-0801 Update Type 1 Diabetics: In June 2018, the company i...
Markets InsiderApr 29
Oramed to Present at ThinkEquity Conference
NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City. Nadav Kidron, CEO of Oramed, will present a corporate overview. Presentation Details: ThinkEquity Conference Date: Thursday, May 2, 2019 Time: 11:30 EDT Location: The Mandarin Orie...
Yahoo FinanceApr 28
Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Slid 60% In The Last Five Years
While not a mind-blowing move, it is good to see that the Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) share price has gained 10% in the last three months. But that doesn't change the fact that the returns over the last half decade have been disappointing. In that time the share price has delivered a rude shock to holders, who find themselves down 60% after a long stretch. So we're not so sure if the recent bounce should be celebrated. Of course, this could be the start of a turnaround. See our latest analysi...
-$0.24 per share
Expected Jun 11, After Hours